Plant & Infrastructure at Mavion Pharmasciences
World-Class Infrastructure

Plant & Infrastructure

Two Facilities in Karnataka, India

We have two facilities located in Karnataka, India. Our state-of-the-art infrastructure forms the backbone of our pharmaceutical API manufacturing capabilities.

  • Spanning 20,000 square meters, our facilities are equipped with cutting-edge technology and industry-leading equipment.
  • These facilities are strategically designed to accommodate diverse manufacturing needs, from laboratory-scale development to large-scale commercial production.
Mavion Unit 1 — state-of-the-art API manufacturing facility
1 / 2
Mavion SS and GL reactors with process equipment
150+ KL Capacity

Installed Reaction Capacity

We have a total installed reaction capacity more than 150 KL, consisting of SS and GL Reactors across our units, varying from 0.6 KL – 6 KL. The downstream equipment for drying, milling, sieving, micronization, and packaging is efficiently installed and operational.

Our utility systems, which include high-pressure boilers (IBR), chilling and cooling systems (500TR), and high-vacuum systems, are instrumental in maximizing output while maintaining low operational costs.

Full Compliance

We offer a range of manufacturing and testing solutions tailored to meet the needs of API manufacturers. Our core competency lies in our manufacturing capabilities, complemented by our proficiency in process development and analytical testing.

The facilities hold full licensing in accordance with the Indian Factory Act and are compliant with, and sanctioned by, WHO GMP, cGMP, ISO 9001:2015, and HACCP standards. Additionally, we have filed for registrations with the EDQM (CEP) and KDMF.
WHO GMP
cGMP
ISO 9001:2015
HACCP
CEP
KDMF
Mavion cGMP compliant manufacturing facility interior
Mavion upcoming GMP manufacturing block — collage
Jan 2027
Commissioning
Expansion Update

Upcoming GMP Intermediate Block

New Production Block to Increase Capacity by 70 KL

We are excited to announce that in the upcoming year, we will begin the construction of a new production block at our facility, set to be ready by Jan 2027. This strategic expansion will enhance our capacity to manufacture Active Pharmaceutical Ingredients (APIs) and meet the growing needs of our customers.

Key Features of the New Production Block

Increased Capacity

The new production block will add a total of 70 KL to our manufacturing capacity.

  • 50KL will be dedicated to intermediate reactions.
  • The remaining 20KL will be housed in a state-of-the-art clean room area to meet stringent quality standards.

Comprehensive Utilities

The new block will include all necessary utilities for optimized production:

  • Cooling and Chilling Systems
  • Vacuum Systems
  • Air Compressors
  • Scrubbing Systems

Facility Size

The new block will cover 3,000 sq. ft., with a total working area of 12,000 sq. ft., providing ample space for efficient manufacturing and streamlined processes.